ESR1 and breast cancer: Our findings establish a comprehensive resource for changes induced in ER+ breast cancer cells by contact with bone marrow MSCs and pinpoint GIV as a promising target to overcome aggressive phenotypes acquired by breast cancer cells in bone marrow.